encouraging phase two outcomes for a new oral Alzheimer's medication.

Published Date: 28 Oct 2023

Based on early data, an investigational dual PPAR agonist modifies the pathology of Alzheimer's disease and exhibits cognitive benefit in adults with mild-to-moderate disease and high plasma pTau-217 ratio.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Stem Cell Selection Unneeded for SSc Transplant Therapy?

2.

Lung Transplant for Lung Cancer: Promising, in Rare Cases

3.

Rural-urban disparities seen in cervical cancer

4.

Obesity linked to subsequent neoplasms in childhood cancer survivors

5.

New policy review highlights the importance of health-related quality of life in advanced cancer


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot